Basilea Pharmaceutica (BPMU.F) Stock Overview
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BPMU.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 71.00 |
| 52 Week High | CHF 74.00 |
| 52 Week Low | CHF 47.50 |
| Beta | 0.45 |
| 1 Month Change | 0% |
| 3 Month Change | 12.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | 38.78% |
| Change since IPO | 40.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| BPMU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | -0.6% |
| 1Y | n/a | 28.2% | 21.7% |
Return vs Industry: Insufficient data to determine how BPMU.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BPMU.F performed against the US Market.
Price Volatility
| BPMU.F volatility | |
|---|---|
| BPMU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BPMU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BPMU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 189 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BPMU.F fundamental statistics | |
|---|---|
| Market cap | US$854.02m |
| Earnings (TTM) | US$51.78m |
| Revenue (TTM) | US$299.00m |
Is BPMU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMU.F income statement (TTM) | |
|---|---|
| Revenue | CHF 232.38m |
| Cost of Revenue | CHF 145.22m |
| Gross Profit | CHF 87.16m |
| Other Expenses | CHF 46.92m |
| Earnings | CHF 40.24m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.27 |
| Gross Margin | 37.51% |
| Net Profit Margin | 17.32% |
| Debt/Equity Ratio | 59.0% |
How did BPMU.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 18:44 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |